Fidaxomicin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 927 publications

Fecal microbiota transplantation versus vancomycin or fidaxomicin in Clostridioides difficile infection first episode and first recurrence: a study protocol for a randomised, controlled, open-label, multicentre phase III clinical trial.

Fecal microbiota transplantation versus vancomycin or fidaxomicin in Clostridioides difficile infection first episode and first recurrence: a study protocol for a randomised, controlled, open-label, multicentre phase III clinical trial.

Journal: BMJ open

Published: August 28, 2026

'Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection' - Author's reply.

'Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection' - Author's reply.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: August 20, 2026

The ongoing challenge of Clostridioides difficile infection in Austria: economic evaluation of two recommended treatment pathways.

The ongoing challenge of Clostridioides difficile infection in Austria: economic evaluation of two recommended treatment pathways.

Journal: Journal of medical economics

Published: August 20, 2026

Characterization of Clostridioides difficile in the U.S. Military, 2016-2024.

Characterization of Clostridioides difficile in the U.S. Military, 2016-2024.

Journal: Military medicine

Published: August 13, 2026

Antibacterial and antivirulence activities of abafungin against Clostridioides difficile: in vitro and in vivo studies.

Antibacterial and antivirulence activities of abafungin against Clostridioides difficile: in vitro and in vivo studies.

Journal: Antimicrobial agents and chemotherapy

Published: August 13, 2026

Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains.

Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains.

Journal: Antimicrobial agents and chemotherapy

Published: August 03, 2026

Clostridioides difficile infection: Current perspectives on diagnosis and therapy

Clostridioides difficile infection: Current perspectives on diagnosis and therapy

Journal: Klinicka mikrobiologie a infekcni lekarstvi

Published: August 01, 2026

Non-Fecal Microbiota Transplantation Strategies for Treatment of Recurrent Clostridioides difficile Infection.

Non-Fecal Microbiota Transplantation Strategies for Treatment of Recurrent Clostridioides difficile Infection.

Journal: Gastroenterology clinics of North America

Published: July 31, 2026

Non-Severe Clostridium difficile Infection.

Non-Severe Clostridium difficile Infection.

Journal: Gastroenterology clinics of North America

Published: July 31, 2026

Re: 'Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection' by Rubio-Martín et al.

Re: 'Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection' by Rubio-Martín et al.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: July 26, 2026

The Impact of Hospital-Based Fidaxomicin Use Criteria on Clostridioides difficile Recurrence: A Retrospective Matched Cohort Study.

The Impact of Hospital-Based Fidaxomicin Use Criteria on Clostridioides difficile Recurrence: A Retrospective Matched Cohort Study.

Journal: Infectious disease reports

Published: July 06, 2026

A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool.

A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool.

Journal: Journal of clinical microbiology

Published: June 12, 2026

Showing 1-12 of 927

Last Updated: 09/26/2026